SCOPUS 정보 검색 플랫폼

Movement Disorders

Volumn 26, Issue 3, 2011, Pages 543-546

Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients

(2) Müller, Thomas a,b Muhlack, Siegfried b

a St Joseph Hospital (Germany)

b ST JOSEF HOSPITAL (Germany)

Author keywords

Cysteinyl glycine; Oxidative stress; Parkinson's disease

Indexed keywords

3 O METHYLDOPA; CARBIDOPA; CYSTEINYLGLYCINE; LEVODOPA;

ABSENCE OF SIDE EFFECTS; ARTICLE; CLINICAL ARTICLE; DISEASE MARKER; DRUG BIOAVAILABILITY; DRUG METABOLISM; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM;

ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; CARBIDOPA; DIPEPTIDES; FEMALE; HUMANS; LEVODOPA; MALE; OXIDATIVE STRESS; PARKINSON DISEASE; TYROSINE;

EID: 79953271910 PISSN: 08853185 EISSN: 15318257 Source Type: Journal
DOI: 10.1002/mds.23384 Document Type: Article

Times cited : (27)

References (8)

1
- 28844480498
- Thiol redox control via thioredoxin and glutaredoxin systems
- Holmgren A, Johansson C, Berndt C, Lonn ME, Hudemann C, Lillig CH. Thiol redox control via thioredoxin and glutaredoxin systems. Biochem Soc Trans 2005; 33(Pt 6): 1375-1377.
- (2005) Biochem Soc Trans , vol.33 , Issue.PART 6 , pp. 1375-1377
- Holmgren, A.¹ Johansson, C.² Berndt, C.³ Lonn, M.E.⁴ Hudemann, C.⁵ Lillig, C.H.⁶

2
- 37549027594
- Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation
- Asanuma M, Miyazaki I, az-Corrales FJ, Miyoshi K, Ogawa N, Murata M. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neurosci Res 2008; 60: 106-113.
- (2008) Neurosci Res , vol.60 , pp. 106-113
- Asanuma, M.¹ Miyazaki, I.² az-Corrales, F.J.³ Miyoshi, K.⁴ Ogawa, N.⁵ Murata, M.⁶

3
- 36049006160
- Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease
- Riederer P, Gerlach M, Müller T, Reichmann H. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 466-479.
- (2007) Parkinsonism Relat Disord , vol.13 , pp. 466-479
- Riederer, P.¹ Gerlach, M.² Müller, T.³ Reichmann, H.⁴

4
- 0026514953
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases
- Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
- (1992) J Neurol Neurosurg Psychiatry , vol.55 , pp. 181-184
- Hughes, A.J.¹ Daniel, S.E.² Kilford, L.³ Lees, A.J.⁴

5
- 38349027133
- Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice
- Chen L, Ding Y, Cagniard B, et al. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 2008; 28: 425-433.
- (2008) J Neurosci , vol.28 , pp. 425-433
- Chen, L.¹ Ding, Y.² Cagniard, B.³

6
- 38949133757
- The role of 3-O-methyldopa in the side effects of L-dopa
- Lee ES, Chen H, King J, Charlton C. The role of 3-O-methyldopa in the side effects of L-dopa. Neurochem Res 2008; 33: 401-411.
- (2008) Neurochem Res , vol.33 , pp. 401-411
- Lee, E.S.¹ Chen, H.² King, J.³ Charlton, C.⁴

7
- 0031790224
- Elevated plasma levels of homocysteine in Parkinson's disease
- Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998; 40: 225-227.
- (1998) Eur Neurol , vol.40 , pp. 225-227
- Kuhn, W.¹ Roebroek, R.² Blom, H.³

8
- 67651146672
- Cysteine elevation in levodopa-treated patients with Parkinson's disease
- Müller T, Kuhn W. Cysteine elevation in levodopa-treated patients with Parkinson's disease. Mov Disord 2009; 24: 929-932.
- (2009) Mov Disord , vol.24 , pp. 929-932
- Müller, T.¹ Kuhn, W.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.